Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
LIVZON PHARMA: Lecankitug Injection Accepted by NMPA for Marketing Authorization Application
Recommend 3 Positive 2 Negative 0 |
||||
|
||||
|
LIVZON PHARMA (01513.HK) announced that Livzon MAB, a controlling subsidiary of the Company, received the Acceptance Notice approved and issued by the National Medical Products Administration (NMPA). The marketing authorization application for the domestically produced drug, Lecankitug Injection jointly developed by Livzon MAB and Beijing Xinkanghe, has been formally accepted by the NMPA. Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
